WebDec 23, 2015 · Norwegian biotech Bionor Pharma has developed an immune-boosting treatment, Vacc-4x, to be used as part of HIV treatment in conjunction with Celgene's romidepsin, which awakens dormant HIV-infected cells. In a clinical study involving 17 HIV-infected patients, Bionor's therapy reduced the size of the latent HIV reservoir by an … WebDec 15, 2016 · bionor pharma asa. stock exchange announcement. not for release, publication or distribution, in whole or in part directly or indirectly, in australia, canada, japan, hong kong or the united states.

A novel peptide-based vaccine candidate with protective efficacy ...

WebFeb 11, 2014 · Bionor Pharma ASA (OSE: BIONOR) announces that the results from the randomized, multicenter, double-blinded, placebo-controlled Phase II trial with 135 patients of the Company's lead candidate Vacc-4x will be published in The Lancet Infectious Diseases and available online at www.thelancet.com as of today. An editorial in the … WebBionor Pharma General Information. Description. Developer of bio-pharmaceutical products intended to focus is the research and development of peptide based vaccines … costi autostrada francia

Bionor Pharma announces acquisition of Solon Eiendom

WebBionor Pharma ASA engages in the development of soy technology for the treatment and prevention of life-style related diseases. It offers Nutrilett and NutriPro, which are health … WebDec 5, 2012 · Bionor Pharma was awarded NOK 10.48 million / US$ 1.85 million from Globvac (Research Council of Norway's program for Global Health- and Vaccine … WebFrom April 2015 to August 2016, I downsized my business to take an in-house SVP, General Counsel and Chief Patent Office position at Bionor Pharma ASA, a public company based in Oslo, Norway ... costiazero monza